IL264640A - - Google Patents

Info

Publication number
IL264640A
IL264640A IL26464019A IL26464019A IL264640A IL 264640 A IL264640 A IL 264640A IL 26464019 A IL26464019 A IL 26464019A IL 26464019 A IL26464019 A IL 26464019A IL 264640 A IL264640 A IL 264640A
Authority
IL
Israel
Application number
IL26464019A
Other languages
English (en)
Other versions
IL264640B2 (en
IL264640B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL264640A publication Critical patent/IL264640A/en
Publication of IL264640B1 publication Critical patent/IL264640B1/en
Publication of IL264640B2 publication Critical patent/IL264640B2/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587Nanoparticles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N2021/258Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plasma & Fusion (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
IL264640A 2016-08-18 2017-08-18 Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy IL264640B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662376788P 2016-08-18 2016-08-18
PCT/US2017/047630 WO2018035470A1 (en) 2016-08-18 2017-08-18 Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy

Publications (3)

Publication Number Publication Date
IL264640A true IL264640A (enExample) 2019-04-30
IL264640B1 IL264640B1 (en) 2023-11-01
IL264640B2 IL264640B2 (en) 2024-03-01

Family

ID=59746357

Family Applications (2)

Application Number Title Priority Date Filing Date
IL264640A IL264640B2 (en) 2016-08-18 2017-08-18 Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
IL307435A IL307435A (en) 2016-08-18 2017-08-18 A test to determine concentration-dependent self-interaction

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL307435A IL307435A (en) 2016-08-18 2017-08-18 A test to determine concentration-dependent self-interaction

Country Status (19)

Country Link
US (3) US11428695B2 (enExample)
EP (2) EP3500856B1 (enExample)
JP (3) JP6959327B2 (enExample)
KR (3) KR102717462B1 (enExample)
CN (2) CN115468919A (enExample)
AU (2) AU2017313150B2 (enExample)
BR (1) BR112019003175A2 (enExample)
CA (3) CA3254461A1 (enExample)
DK (2) DK3761035T3 (enExample)
EA (1) EA201990316A1 (enExample)
ES (2) ES2837093T3 (enExample)
FI (1) FI3761035T3 (enExample)
HU (2) HUE066064T2 (enExample)
IL (2) IL264640B2 (enExample)
MX (2) MX2019001930A (enExample)
PL (2) PL3500856T3 (enExample)
SG (1) SG11201900895QA (enExample)
WO (1) WO2018035470A1 (enExample)
ZA (1) ZA201901035B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL264640B2 (en) 2016-08-18 2024-03-01 Regeneron Pharma Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度vegf受容体融合タンパク質を含む製剤
CN113588582B (zh) * 2020-04-30 2024-05-14 上海药明生物技术有限公司 蛋白质样品浓度测定方式选择法及测定方法
WO2023095154A1 (en) * 2021-11-24 2023-06-01 Sensoville Biotech Pvt Ltd Method for determining changes in a protein's structure
EP4469801A1 (en) * 2022-01-24 2024-12-04 Amgen Inc. Methods for detecting antibody self-association
CN119832975A (zh) * 2024-12-24 2025-04-15 上海药明生物技术有限公司 一种蛋白质共处方制剂的稳定性预测方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US771997A (en) 1903-11-21 1904-10-11 Alfred Palm Lathe attachment.
US4254102A (en) * 1975-09-08 1981-03-03 Plough, Inc. Substantive PABA compositions
US4080264A (en) 1976-03-01 1978-03-21 Massachusetts Institute Of Technology Immunoassay by light scattering spectroscopy
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US20050214356A1 (en) * 2004-03-24 2005-09-29 Joyce Timothy H Self assembling activation agents targeted using active drug release
US20050221507A1 (en) * 2004-03-30 2005-10-06 Intel Corporation Method to detect molecular binding by surface-enhanced Raman spectroscopy
US7514938B2 (en) 2004-05-11 2009-04-07 Board Of Regents Of The University And College System Of Nevada, On Behalf Of The University Of Nevada, Reno Dielectric relaxation spectroscopy apparatus and methods of use
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
CN101238141B (zh) * 2005-05-02 2016-10-12 巴斯福股份公司 灵敏检测分析物的新标记策略
WO2007121363A2 (en) 2006-04-13 2007-10-25 Mississippi State University An optical apparatus for simultaneously measuring the scattering and concentration signals of macromolecules in a flow cell
MX2009003542A (es) 2006-10-12 2009-04-15 Wyeth Corp Metodos y composiciones con opalescencia reducida.
GB0621050D0 (en) * 2006-10-23 2006-11-29 Univ Strathclyde Functionalised polymers for labelling metal surfaces
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
JP2011520769A (ja) * 2007-09-21 2011-07-21 サイトイミューン サイエンシズ インコーポレイテッド ナノ治療コロイド金属組成物および方法
US20110305765A1 (en) 2008-11-21 2011-12-15 Board Of Regents, The University Of Texas System Preparation and methodology of silk fibroin nanoparticles
US20140024024A1 (en) * 2012-07-17 2014-01-23 General Electric Company Methods of detecting dna, rna and protein in biological samples
WO2014192937A1 (ja) * 2013-05-30 2014-12-04 公立大学法人大阪府立大学 被検出物質の検出装置および方法
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP2902503A1 (en) * 2014-01-31 2015-08-05 Fundación Imdea Nanociencia Functionalized metal nanoparticles and uses thereof for detecting nucleic acids
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
CN104062287B (zh) 2014-07-01 2017-08-08 福建工程学院 一种基于纳米金催化的化学发光分析检测铁蛋白的方法
MA40861A (fr) * 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
US20180264112A1 (en) * 2015-01-18 2018-09-20 Biogen Ma Inc. Anti-CD40 Antibody Formulations
IL264640B2 (en) 2016-08-18 2024-03-01 Regeneron Pharma Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy

Also Published As

Publication number Publication date
AU2017313150B2 (en) 2023-09-14
WO2018035470A9 (en) 2018-07-05
CN109661577A (zh) 2019-04-19
PL3761035T3 (pl) 2024-06-24
CN115468919A (zh) 2022-12-13
CA3032361A1 (en) 2018-02-22
KR20190039185A (ko) 2019-04-10
US11988668B2 (en) 2024-05-21
AU2017313150A1 (en) 2019-02-21
ES2837093T3 (es) 2021-06-29
KR20230074614A (ko) 2023-05-30
AU2023274236A1 (en) 2023-12-21
CA3254461A1 (en) 2025-07-03
CA3254460A1 (en) 2025-07-03
HUE052805T2 (hu) 2021-05-28
EP3761035B1 (en) 2024-02-14
ES2974961T3 (es) 2024-07-02
US20220357335A1 (en) 2022-11-10
EP3500856B1 (en) 2020-10-07
DK3500856T3 (da) 2020-12-14
MX2023013583A (es) 2023-11-30
SG11201900895QA (en) 2019-02-27
IL264640B2 (en) 2024-03-01
IL264640B1 (en) 2023-11-01
ZA201901035B (en) 2024-06-26
PL3500856T3 (pl) 2021-04-19
KR20220126801A (ko) 2022-09-16
MX2019001930A (es) 2019-07-04
US20190187149A1 (en) 2019-06-20
JP2019532267A (ja) 2019-11-07
BR112019003175A2 (pt) 2019-06-18
EA201990316A1 (ru) 2019-07-31
US20240280582A1 (en) 2024-08-22
FI3761035T3 (fi) 2024-03-18
IL307435A (en) 2023-12-01
KR102534506B1 (ko) 2023-05-30
KR102717462B1 (ko) 2024-10-16
EP3500856A1 (en) 2019-06-26
JP2023139189A (ja) 2023-10-03
CN109661577B (zh) 2022-09-27
JP7321227B2 (ja) 2023-08-04
EP3761035A1 (en) 2021-01-06
KR102441221B1 (ko) 2022-09-07
WO2018035470A1 (en) 2018-02-22
CA3032361C (en) 2025-07-08
HUE066064T2 (hu) 2024-07-28
DK3761035T3 (da) 2024-03-11
JP2022008959A (ja) 2022-01-14
JP6959327B2 (ja) 2021-11-02
US11428695B2 (en) 2022-08-30

Similar Documents

Publication Publication Date Title
BR112019002665A2 (enExample)
BR112018004986A2 (enExample)
BR112019001429A2 (enExample)
BR212018070320U2 (enExample)
BR112019011044B1 (pt) Compostos de pirazol substituído, seu uso, e composição farmacêutica
BR112019008501B1 (pt) Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador
BR112019003116B1 (pt) Configuração de símbolo de rajada comum de uplink
BR112018076018B1 (pt) Método de processamento de sms na internet das coisas, elemento de rede de gerenciamento de mobilidade, e dispositivo terminal
BR112018076493B1 (pt) Sistemas e métodos para detecção de posição de feixe de luz
BR112018073794B1 (pt) Partícula, método de geração da partícula, vacina ou composição farmacêutica
BR122026002520A2 (pt) Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno
BR112019006736A2 (enExample)
BR102016018018A2 (enExample)
BE2016C016I2 (enExample)
CN303537476S (enExample)
CN303536593S (enExample)
CN303545385S (enExample)
CN303635734S (enExample)
CN303536207S (enExample)
CN303551088S (enExample)
CN303273880S8 (enExample)
CN303537442S (enExample)
CN303606727S (enExample)
CN303627654S (enExample)
CN303537535S (enExample)